More information about text formats
This is an interesting paper; however I was surprised at the vagueness of the conclusion. The authors showed a significantly increased 'ratio of lymphoma' with adalimumab (4.1) and infliximab (3.6) vs. entanercept
(0.9). Unless some confounding variable is discovered, the conclusion would seem clear. Either adalimumab and infliximab predispose to lymphoma, or entanercept prevents it.
The 'conclusion' that the general "two to threefold" increase is "similar to that expected" may suggest the latter explanation is indeed possible, but seems rather to miss the point and suggests on the part of the authors
either a lack of confidence in their own data or a wish not to offend.